Empathbio Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Empathbio inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Empathbio Inc Today - Breaking & Trending Today

Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD


News Category Global Banking & Finance Reviews
Joint feasibility assessment of Bionomics BNC210 and EmpathBio s MDMA derivative EMP-01 treatment regimen for PTSD
ADELAIDE, Australia, Feb. 17, 2021 /PRNewswire/
 Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5) (
Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (
EmpathBio), a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences (
atai). Under the Memorandum of Understanding, Bionomics and EmpathBio propose to collectively explore a combination drug treatment regimen with Bionomics BNC210 and EmpathBio s 3,4-Methylenedioxymethamphetamine (MDMA) derivative EMP-01. The parties will explore whether the different mechanisms of action of EMP-01 and BNC210 may offer the potential for developing an improved treatment regimen for the treatment of Post-Traumatic Stress Disorder (PTSD). ....

South Australia , Life Sciences , Empathbio Inc , Multidisciplinary Association For Psychedelic Studies , Drug Administration , Merck Co , Bionomics Limited , Post Traumatic Stress Disorder , Fast Track , Breakthrough Therapy , Multidisciplinary Association , Psychedelic Studies , Executive Chairman , Glenn Short , Florian Brand , தெற்கு ஆஸ்திரேலியா , வாழ்க்கை அறிவியல் , பலதரப்பட்ட சங்கம் க்கு சைகடெலிக் ஆய்வுகள் , மெர்க் இணை , போஸ்ட் அதிர்ச்சிகரமான மன அழுத்தம் கோளாறு , வேகமாக டிராக் , திருப்புமுனை சிகிச்சை , பலதரப்பட்ட சங்கம் , சைகடெலிக் ஆய்வுகள் , நிர்வாகி தலைவர் , க்ளென் குறுகிய ,

Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD


 Bionomics Limited (ASX: BNO,OTCQB: BNOEF, Germany: AU000000BNO5) (
Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (
EmpathBio), a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences (
atai). Under the Memorandum of Understanding, Bionomics and EmpathBio propose to collectively explore a combination drug treatment regimen with Bionomics BNC210 and EmpathBio s 3,4-Methylenedioxymethamphetamine (MDMA) derivative EMP-01. The parties will explore whether the different mechanisms of action of EMP-01 and BNC210 may offer the potential for developing an improved treatment regimen for the treatment of Post-Traumatic Stress Disorder (PTSD).
BNC210 is Bionomics lead drug candidate, which has been granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of PTSD and other trauma-related and stress-related disorders. A new solid dose formulati ....

South Australia , Life Sciences , Multidisciplinary Association For Psychedelic Studies , Empathbio Inc , Drug Administration , Merck Co , Bionomics Limited , Post Traumatic Stress Disorder , Fast Track , Breakthrough Therapy , Multidisciplinary Association , Psychedelic Studies , Executive Chairman , Glenn Short , Florian Brand , Health Care Amp Hospitals , Small Cap , Medical Pharmaceuticals , Mental Health , தெற்கு ஆஸ்திரேலியா , வாழ்க்கை அறிவியல் , பலதரப்பட்ட சங்கம் க்கு சைகடெலிக் ஆய்வுகள் , மெர்க் இணை , போஸ்ட் அதிர்ச்சிகரமான மன அழுத்தம் கோளாறு , வேகமாக டிராக் , திருப்புமுனை சிகிச்சை ,